Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase Ib/IIa Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of TNM001 Injection in Chinese Healthy Preterm and Term Infants
NCT05630573 is registered in ClinicalTrials.gov with Zhuhai Trinomab Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase Ib/IIa Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of TNM001 Injection in Chinese Healthy Preterm and Term Infants
- Lead sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- October 25, 2022
- Completion date
- June 30, 2023
- Enrollment
- 31 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.